PBRM1 and renal cell adenocarcinoma: (2021) employed a droplet-based PCR microchip to identify VHL and PBRM1 mutations in plasma ctDNA from RCC patients, facilitating dynamic treatment monitoring and non-invasive molecular profiling (154).